Comprehensive Review of Conventional, Targeted, Immunological and Emerging Therapies in Cancer Treatment

Vaibhav S. Gite¹, Rupali N. Nikam¹, Mukund M. Pache¹, Pragati B. Wankhede¹,

Sagar S.  Pawale¹, Avinash B. Darekar²

¹Department of Pharmacology, K.V.N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education & Research, Nashik, 422 002, Maharashtra, India.

²Principal, K. V. N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education & Research, Nashik, 422 002, Maharashtra, India.

*Corresponding Author E-mail: mukundpache918@mail.com

ABSTRACT:

Cancer remains a major global health challenge, causing nearly 10 million deaths annually. Advances in biomedical science have expanded treatment beyond conventional chemotherapy and radiotherapy to include targeted molecular agents, immunotherapies, and novel modalities. This review summarises cancer therapeutics across four domains: conventional, targeted, immunological, and emerging approaches. We examine the mechanisms, clinical efficacy, limitations, and innovations, outlining the evolution of oncological care and the integration of opportunities. Conventional modalities such as surgery, chemotherapy, and radiotherapy are discussed for their cytotoxic mechanisms and role in localised disease. Targeted therapies, including kinase inhibitors and monoclonal antibodies, are evaluated for molecular specificity and resistance. Immunological strategies, particularly immune checkpoint inhibitors and CAR-T cell therapy, are evaluated for their transformative impact. Emerging treatments, including oncolytic viruses, gene editing, and nanotechnology-based systems, are appraised for innovation and translational potential. While traditional methods retain relevance, combining them with precision medicine and immunological advances has yielded unprecedented efficacy in certain cancers. The future lies in personalised, synergistic regimens across these domains, supported by sustained interdisciplinary research and clinical validation.

KEYWORDS: Cancer therapy, Conventional treatment, Targeted therapy, Immunotherapy, Emerging therapies, Personalised medicine, Precision oncology.

INTRODUCTION:

Cancer is a leading cause of morbidity and mortality worldwide, with an estimated 19.3 million new cases and 10 million cancer-related deaths reported in 2020 alone. The global burden of cancer is projected to rise significantly over the coming decades, driven by ageing populations, environmental exposures, and lifestyle factors.¹ The heterogeneous nature of cancer, characterised by distinct genetic, epigenetic, and phenotypic alterations across tumour types, further complicates its management and underscores the need for diversified treatment strategies.²

Historically, the primary treatment modalities for cancer included surgery, chemotherapy, and radiotherapy. These conventional approaches, while effective for many localised and rapidly proliferating tumours, often lacked specificity and were associated with significant collateral damage to healthy tissues. The limitations of such non-discriminatory treatments became increasingly apparent, leading to the development of more precise and targeted therapeutic interventions.³

Advances in molecular biology and genomics have enabled targeted therapies such as tyrosine kinase inhibitors and monoclonal antibodies, improving efficacy and reducing toxicity in selected patients. Breakthroughs in immunology have led to immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, achieving significant success in certain cancers. Concurrently, emerging approaches—including oncolytic virotherapy, CRISPR-based gene editing, nanomedicine, and microbiome modulation—are expanding the therapeutic landscape. While many remain in early clinical stages, these innovations hold promise to address unmet needs and transform cancer care.⁴

Figure 1.  Global Cancer Mortality by Continent in 2022⁵

This review aims to delineate the mechanistic underpinnings, clinical applications, benefits, and limitations of each therapeutic category. By integrating insights from preclinical studies, clinical trials, and real-world evidence, we aim to provide a comprehensive narrative that informs both current clinical practice and future innovation. Ultimately, this work endeavours to contribute to the optimisation of personalised, effective, and durable cancer care.

Table 1. Overview of Major Cancer Treatment Modalities

Therapy Type	Mechanism of Action	Typical Indications	Advantages	Limitations/ Challenges
Surgery	Physical removal of the tumour and surrounding tissues	Solid tumours (early-stage breast, colon, lung)	Curative in localised disease	Ineffective in metastasis, invasive, and recurrence
Radiotherapy	Ionising radiation damages the DNA of cancer cells, leading to apoptosis	Prostate, brain, head & neck, cervical cancers	Non-invasive; can preserve organs	Radiation toxicity; secondary malignancy risk
Chemotherapy	Cytotoxic agents disrupt cell division, DNA replication	Hematologic and solid tumours	Systemic; suitable for disseminated disease	Non-specific toxicity, resistance, and side effects
Targeted Therapy	Blocks specific molecular pathways (e.g., EGFR, VEGF, BRAF)	Lung, melanoma, breast (HER2+), leukaemia	Precision approach; often oral agents	Resistance mutations; expensive
Immunotherapy	Activates the immune system via checkpoint inhibitors, CAR-T, and cytokines	Melanoma, NSCLC, Hodgkin’s lymphoma	Durable responses; immune memory	Immune-related AEs; non-responders
Emerging Therapies	Novel methods: oncolytic viruses, nanocarriers, CRISPR, AI-guided therapy	Experimental/clinical trials for many cancers	Highly innovative, personalised potential	Limited approval, scalability, and regulatory hurdles

1. Conventional Therapies:

Conventional cancer therapies- surgery, radiotherapy, and chemotherapy have long served as the foundation of oncological treatment. Despite their non-specific mechanisms and associated toxicities, these modalities remain indispensable in managing various cancer types, particularly in early-stage and localised disease. Their continued refinement, guided by clinical data and multidisciplinary coordination, underscores their relevance in modern oncology.

Surgery:

Surgical resection is often the first-line treatment for solid tumours, particularly when detected at an early stage. Its primary objective is complete excision of the tumour with clear margins to minimise recurrence. Surgery offers curative potential in many cancers, such as breast, colorectal, prostate, and lung, when confined to a single anatomical region. It also plays a critical role in debulking tumours before adjuvant therapy and in palliative settings to relieve symptoms and improve quality of life.⁶

Advances in imaging, surgical techniques, and perioperative care have significantly improved surgical outcomes. Minimally invasive approaches, including laparoscopic and robotic-assisted procedures, have reduced operative morbidity and hospital stays. Sentinel lymph node biopsy and intraoperative navigation systems further enhance precision, optimising oncologic control while preserving function.⁷

However, surgical intervention is limited in metastatic or inoperable tumours, and recurrence remains a concern despite clear margins. The integration of surgery with adjuvant or neoadjuvant therapies aims to overcome these limitations by reducing micrometastatic disease and improving long-term survival.⁸

Radiotherapy:

Radiotherapy utilises ionising radiation to induce DNA damage and cellular apoptosis in rapidly dividing cancer cells. Approximately 50% of cancer patients receive radiotherapy during their disease. It is used as a curative, adjuvant, neoadjuvant, or palliative treatment, often in combination with surgery or chemotherapy.⁹

External beam radiotherapy (EBRT), the most common modality, delivers high-energy x-rays or particles to the tumour site while minimising exposure to surrounding tissues through image-guided and intensity-modulated techniques. Brachytherapy, which involves the placement of radioactive sources within or near the tumour, delivers a high dose to the target with minimal systemic effects, and is particularly effective in gynaecologic and prostate cancers.

Despite its efficacy, radiotherapy can lead to acute and chronic toxicities such as skin changes, mucositis, organ dysfunction, and secondary malignancies. Technological advancements, including stereotactic body radiotherapy (SBRT) and proton therapy, aim to enhance precision and reduce collateral damage.¹⁰

Chemotherapy:

Chemotherapy employs cytotoxic agents to target proliferating cancer cells by disrupting cell division. Drug classes include alkylating agents, antimetabolites, anthracyclines, taxanes, and vinca alkaloids, each with distinct mechanisms and toxicity profiles. Chemotherapy is used across treatment settings- curative, adjuvant, neoadjuvant, and palliative, depending on tumour type and stage ^11,12

Despite its broad applicability, chemotherapy's non-selectivity results in damage to rapidly dividing normal cells, leading to adverse effects such as myelosuppression, mucositis, alopecia, and gastrointestinal toxicity. Dosing schedules and supportive care are critical in mitigating these toxicities.

Multidrug regimens, dose-dense protocols, and regional delivery methods (e.g., intrathecal or intra-arterial) have been developed to enhance efficacy. Nonetheless, inter-patient variability, tumour heterogeneity, and resistance mechanisms continue to challenge therapeutic outcomes.^13,14

Table 2. Cytotoxic Chemotherapy Agents – Classes and Mechanisms

Class	Example Drugs	Mechanism of Action	Cancers Treated	Major Side Effects
Alkylating Agents	Cyclophosphamide, Ifosfamide	Cross-links DNA strands, inhibiting replication	Lymphomas, breast, ovarian, and sarcomas	Myelosuppression, haemorrhagic cystitis
Antimetabolites	Methotrexate, 5-FU, Gemcitabine	Mimic nucleotides inhibit DNA/RNA synthesis	Colorectal, pancreatic, leukaemia	Mucositis, myelosuppression
Topoisomerase Inhibitors	Irinotecan, Etoposide, Doxorubicin	Inhibit enzymes involved in DNA unwinding	Lung, ovarian, lymphomas, sarcomas	Cardiotoxicity (doxorubicin), diarrhoea
Antimicrotubular Agents	Paclitaxel, Vincristine	Block microtubule polymerisation or depolymerisation	Breast, lung, ovarian, and lymphoma	Neuropathy, alopecia
Platinum-based Compounds	Cisplatin, Carboplatin, Oxaliplatin	Form DNA crosslinks, disrupting replication	Testicular, lung, head & neck, colorectal	Nephrotoxicity, ototoxicity
Others (Misc.)	Bleomycin, Mitomycin	Various DNA-damaging effects	Testicular, bladder, and squamous carcinomas	Pulmonary fibrosis (bleomycin)

Conventional cancer therapies remain integral to modern oncologic practice, especially for early-stage disease and as components of multimodal regimens. While significant strides have been made in minimising toxicity and improving precision, challenges such as resistance and long-term sequelae persist. Continued adherence to evidence-based guidelines such as those from the National Comprehensive Cancer Network (NCCN), as well as real-world epidemiological insights from SEER and WHO data, will be critical in optimising the use of these foundational therapies in an evolving therapeutic landscape.¹⁵

2. Targeted Therapies:

The advent of targeted cancer therapies has marked a transformative shift from cytotoxic approaches to precision medicine. Unlike traditional chemotherapeutic agents that indiscriminately affect all rapidly dividing cells, targeted therapies are designed to interfere with specific molecular pathways critical for tumour growth and survival. This section examines the most clinically impactful targeted therapies, including receptor tyrosine kinase inhibitors (RTKIs), angiogenesis inhibitors, and poly (ADP-ribose) polymerase (PARP) inhibitors, as well as the challenges of therapeutic resistance and the current clinical trial landscape.¹⁶

Receptor Tyrosine Kinase Inhibitors:

Receptor tyrosine kinases (RTKs) play pivotal roles in cellular signalling processes that regulate proliferation, differentiation, and survival. Aberrant RTK signalling via mutations, amplifications, or overexpression is a hallmark of many malignancies. The development of RTKIs has allowed for selective inhibition of these oncogenic drivers.¹⁷

Epidermal growth factor receptor (EGFR) mutations are prevalent in non-small cell lung cancer (NSCLC). First-generation inhibitors, such as gefitinib and erlotinib, demonstrated clinical efficacy, followed by second-generation afatinib and third-generation Osimertinib, which address T790 M-mediated resistance. HER2-targeted agents such as trastuzumab and lapatinib have shown significant success in HER2-positive breast and gastric cancers, particularly when combined with chemotherapy.

Resistance to RTKIs arises through secondary mutations (e.g., EGFR T790M, HER2 L755S), activation of bypass signalling (e.g., MET, AXL), and histologic transformation. These insights have informed sequential therapy designs and combination strategies to forestall resistance.¹⁸

Angiogenesis Inhibitors:

Angiogenesis, the formation of new blood vessels, is crucial for tumour growth and metastasis. Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) are key mediators of this process. Bevacizumab, a monoclonal antibody against VEGF-A, was the first anti-angiogenic agent approved for cancer treatment.¹⁹

Bevacizumab has shown efficacy in metastatic colorectal cancer, NSCLC, renal cell carcinoma, and glioblastoma. Other agents, such as ramucirumab (a VEGFR2 antibody) and multi-kinase inhibitors (sunitinib, sorafenib), extend angiogenic blockade across diverse tumour types. Despite initial responses, resistance often develops through upregulation of alternative pro-angiogenic factors (e.g., FGF, PDGF), increased pericyte coverage, and vascular mimicry. Combination with immunotherapy and targeted agents is under investigation to prolong response durability and overcome resistance.¹⁹

PARP Inhibitors in BRCA-Mutated Cancers:

Poly (ADP-ribose) polymerase (PARP) inhibitors exploit the concept of synthetic lethality in tumours with homologous recombination repair deficiencies, notably BRCA1/2 mutations. By blocking PARP-mediated single-strand break repair, these agents induce genomic instability and apoptosis in BRCA-mutant cancer cells.²⁰

Olaparib, rucaparib, niraparib, and Talazoparib have gained FDA approval for use in BRCA-mutated breast, ovarian, pancreatic, and prostate cancers. PARP inhibitors are generally well-tolerated, although hematologic toxicities and gastrointestinal side effects are common.

Targeted therapies have revolutionised the oncology landscape, offering improved specificity and reduced systemic toxicity. However, the inevitability of resistance necessitates adaptive treatment strategies and continued innovation. Integration of genomic profiling, real-time biomarker monitoring, and novel drug designs will be critical in maximising the potential of precision oncology.

3. Immunological Therapies:

The emergence of immunological therapies has redefined the therapeutic landscape of oncology, harnessing the immune system's intrinsic capacity to detect and eliminate malignant cells. This paradigm shift is supported by a growing understanding of tumour immunobiology and the mechanisms by which cancer evades immune surveillance. Key immunotherapeutic modalities include immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapy, cancer vaccines, and cytokine-based therapies. While demonstrating unprecedented clinical successes, these interventions are accompanied by unique toxicity profiles and complex resistance mechanisms.^21,22

Checkpoint Inhibitors: PD-1, PD-L1, and CTLA-4:

Immune checkpoints are regulatory pathways that maintain immune homeostasis and prevent autoimmunity. Tumours exploit these pathways to suppress anti-tumour immunity, primarily through the upregulation of PD-L1 (Programmed Death Ligand 1) and interaction with PD-1 (Programmed Death-1) receptors on T cells. Immune checkpoint inhibitors (ICIs) disrupt this interaction, thereby restoring T-cell activity.²³

Anti-PD-1 agents, such as pembrolizumab and nivolumab, and anti-PD-L1 agents, like atezolizumab and durvalumab, have demonstrated efficacy in various cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and triple-negative breast cancer, among others. The anti-CTLA-4 antibody ipilimumab, initially approved for the treatment of advanced melanoma, functions by enhancing T-cell priming and activation in lymphoid tissues.

Landmark trials include KEYNOTE-024 (pembrolizumab in non-small cell lung cancer), CheckMate-067 (nivolumab plus ipilimumab in melanoma), and IMpower110 (atezolizumab in PD-L1-high non-small cell lung cancer). These studies established durable responses and prolonged overall survival (OS) in select patient populations.²⁴

Figure 2. PD-1/PD-L1 pathway contributes to tumour immune escape, enabling tumours to evade immune response.²⁵

CAR-T Therapy: Successes in Hematologic Cancers:

CAR-T cell therapy involves the ex vivo genetic engineering of autologous T cells to express synthetic receptors targeting tumour-specific antigens. Upon reinfusion, these cells exhibit potent cytotoxic activity independent of MHC presentation.²⁶

CD19-directed CAR-T products, tisagenlecleucel and axicabtagene ciloleucel, have demonstrated remarkable success in B-cell malignancies, including relapsed or refractory Acute Lymphoblastic Leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Response rates often exceed 80%, with durable remissions reported in a subset of patients.

Ongoing challenges include manufacturing complexity, limited efficacy in solid tumours due to antigen heterogeneity and the immunosuppressive tumour microenvironment, and severe toxicities such as cytokine release syndrome (CRS) and neurotoxicity.

Cancer Vaccines: Therapeutic vs. Prophylactic:

Cancer vaccines aim to induce or enhance an immune response against tumour-associated antigens (TAAs). Prophylactic vaccines, such as those targeting human papillomavirus (HPV) and hepatitis B virus (HBV), have successfully reduced the incidence of cervical and hepatocellular cancers, respectively.²⁷

Therapeutic vaccines target existing tumours and are categorised into peptide-based, dendritic cell-based, and nucleic acid-based formulations. Sipuleucel-T, approved for metastatic castration-resistant prostate cancer, remains the only therapeutic cancer vaccine with regulatory approval. However, clinical outcomes have been modest, with most candidates failing to demonstrate significant survival benefits.²⁸

Emerging strategies aim to enhance immunogenicity through the use of adjuvants, in combination with immune checkpoint inhibitors (ICIs), and personalisation using neoantigen prediction algorithms.

Cytokine Therapies: IL-2 and Interferons:

Cytokines such as interleukin-2 (IL-2) and interferons (IFNs) were among the first Immunotherapeutics used in cancer treatment. High-dose IL-2 has demonstrated durable responses in metastatic melanoma and renal cell carcinoma, attributed to its ability to activate natural killer (NK) cells and cytotoxic T cells.²⁹

Interferon-alpha has been employed in hematologic malignancies and as adjuvant therapy in melanoma. Despite demonstrated efficacy, widespread use has declined due to systemic toxicities including capillary leak syndrome, neuropsychiatric effects, and hematologic suppression. Next-generation cytokine therapies, including engineered IL-2 variants (e.g., bempegaldesleukin), aim to reduce toxicity and selectively stimulate effector over regulatory T cells.³⁰

Toxicities: Immune-Related Adverse Events (irAEs):

Immune checkpoint inhibitors and CAR-T therapies are associated with unique adverse events termed immune-related adverse events (irAEs), stemming from nonspecific immune activation. Common immune-related adverse events (irAEs) include dermatitis, colitis, hepatitis, endocrinopathies (thyroiditis, hypophysitis), and pneumonitis. While most are manageable with corticosteroids and immunosuppressants, severe or refractory cases can be life-threatening. The incidence and severity of irAEs correlate with therapeutic potency and combination regimens (e.g., dual CTLA-4 and PD-1 blockade).³¹

CAR-T-related toxicities, particularly CRS and immune effector cell-associated neurotoxicity syndrome (ICANS), require prompt recognition and management with tocilizumab and corticosteroids. Risk mitigation involves pre-treatment screening, biomarker development, and the establishment of clinical guidelines for early intervention and treatment.^32,33

Immunological therapies represent a cornerstone of modern oncology, offering long-lasting responses and potential cures in historically recalcitrant cancers. While immune-mediated toxicities and resistance mechanisms remain significant challenges, ongoing research into biomarkers, combination strategies, and next-generation immunomodulators promises to extend the reach and durability of these transformative therapies.

4. Emerging Therapies:

The dynamic and rapidly evolving field of oncology has spurred the development of innovative therapeutic modalities that transcend traditional treatment paradigms. These emerging therapies harness breakthroughs in virotherapy, gene editing, nucleic acid technologies, nanomedicine, and artificial intelligence (AI) to address unmet clinical needs and enhance therapeutic precision. Though many remain in experimental or early clinical phases, the transformative potential of these strategies is increasingly evident. This section explores five key categories of emerging cancer therapies, highlighting their mechanisms, clinical progress, and future implications.^34,35

Oncolytic Viruses (e.g., T-VEC):

Oncolytic virotherapy employs genetically engineered or naturally occurring viruses that selectively infect, replicate within, and lyse cancer cells, while simultaneously stimulating antitumour immunity. Talimogene laherparepvec (T-VEC), an engineered herpes simplex virus type 1 expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), is the first FDA-approved oncolytic virus for the treatment of melanoma.³⁶

T-VEC demonstrated modest improvements in durable response rates in phase III trials and has been integrated into combination regimens with checkpoint inhibitors to enhance efficacy. Other candidates under investigation include oncolytic adenoviruses, reoviruses, and vaccinia viruses. While promising, limitations include intratumoural delivery requirements, host immune neutralisation, and tumour microenvironment heterogeneity.³⁷

CRISPR and Gene Editing:

CRISPR-Cas9 and other gene editing platforms offer precise genomic modifications, enabling correction of oncogenic mutations, disruption of drug resistance mechanisms, and enhancement of immune cell function. In cancer therapy, CRISPR has primarily been utilised to engineer T cells for improved antitumour activity.^38,39

Early-phase clinical trials have explored CRISPR-edited T cells lacking PD-1 or endogenous TCRs in hematologic malignancies and solid tumours. Notably, a 2020 first-in-human study demonstrated the safety and feasibility of CRISPR-engineered T cells in patients with refractory cancers. Future directions include in vivo gene editing, base editing, prime editing, and multiplexed genome modulation.⁴⁰

Despite its promise, challenges persist in terms of delivery efficiency, off-target effects, immune responses to Cas proteins, and ethical considerations.

mRNA Platforms (e.g., BioNTech–Moderna Innovations):

The success of mRNA vaccines in the COVID-19 pandemic has catalysed interest in applying mRNA technology to cancer therapeutics. mRNA-based cancer vaccines encode tumour-specific antigens to stimulate an adaptive immune response. Unlike conventional vaccines, mRNA platforms offer rapid manufacturing, customisable antigen selection, and potent immunogenicity.⁴¹

BioNTech and Moderna are leading efforts to develop individualised neoantigen vaccines based on patient-specific tumour mutational profiles. Early trials, including BioNTech’s BNT122 in melanoma and Moderna’s mRNA-4157 in head and neck cancers, have shown favourable safety and immunogenicity. These vaccines are often administered in combination with checkpoint inhibitors to enhance their efficacy.⁴²

Challenges include antigen selection, delivery efficiency, and immune evasion by tumours. However, the adaptability of mRNA platforms positions them as a promising component of future immuno-oncology regimens.

Nanoparticle-Based Drug Delivery:

Nanotechnology has enabled the development of drug delivery systems that enhance therapeutic index by improving tumour targeting, bioavailability, and controlled release. Nanoparticles can encapsulate chemotherapeutics, nucleic acids, or imaging agents, facilitating precise delivery to the tumour microenvironment.⁴³

Liposomal formulations, such as liposomal doxorubicin (Doxil) and albumin-bound paclitaxel (Abraxane), have demonstrated clinical benefits with reduced systemic toxicity. Ongoing research is focused on stimuli-responsive, tumour-penetrating, and immune-modulating nanoparticles. Multifunctional nanocarriers are being designed to co-deliver drugs and adjuvants or respond to pH, enzymatic, or thermal triggers. Despite technical challenges in large-scale production and regulatory approval, nanomedicine represents a frontier in personalised oncologic drug delivery.⁴⁴

Artificial Intelligence in Therapy Design:

AI and machine learning algorithms are increasingly employed in drug discovery, biomarker identification, clinical trial design, and personalised treatment planning. In oncology, AI facilitates high-throughput analysis of genomic, proteomic, and imaging data to predict therapeutic response and resistance. AI-driven platforms have accelerated the identification of novel drug targets and optimised compound screening. For example, DeepMind’s AlphaFold has revolutionised protein structure prediction, enabling rational drug design.^45,46

Clinical applications include AI-assisted radiomics for treatment monitoring, natural language processing for clinical decision support, and predictive modelling for trial stratification. While challenges remain in data integration, validation, and regulatory oversight, AI holds the potential to transform cancer therapy from discovery to bedside.⁴⁷

Emerging cancer therapies represent the convergence of molecular biology, engineering, and data science to overcome the limitations of conventional and existing treatments. While still in early phases, these innovations hold the promise of transforming cancer care through enhanced specificity, adaptability, and personalisation. Continued investment in translational research, interdisciplinary collaboration, and ethical governance will be critical to realising their full potential.⁴⁸

5. Comparative Efficacy & Challenges:

The proliferation of cancer treatment modalities has ushered in an era of therapeutic abundance; however, this diversity necessitates rigorous comparative evaluation. To optimise outcomes and align therapies with individual patient needs, it is essential to assess overall survival (OS), progression-free survival (PFS), toxicity profiles, and treatment accessibility. This section synthesises the comparative efficacy of major therapeutic domains, conventional, targeted, immunological, and emerging therapies, while also addressing the real-world challenges of global accessibility, combinatorial strategies, and systemic limitations.⁴⁹

Efficacy: OS and PFS Comparisons:

Conventional therapies, such as chemotherapy and radiotherapy, have demonstrated modest improvements in Overall Survival (OS) and Progression-Free Survival (PFS) across a range of solid tumours. For example, platinum-based chemotherapy in Non-Small Cell Lung Cancer (NSCLC) yields a median OS of approximately 10–12 months, with significant toxicity. Targeted therapies have demonstrated superior progression-free survival (PFS) in molecularly selected populations. Osimertinib in EGFR-mutant non-small cell lung cancer (NSCLC) improved median progression-free survival (PFS) to 18.9 months and overall survival (OS) to over 38 months in the FLAURA trial.⁵⁰

Immune checkpoint inhibitors have delivered durable responses in select cancers. In the KEYNOTE-024 trial, pembrolizumab monotherapy extended the median overall survival (OS) to 26.3 months in patients with PD-L1-high non-small cell lung cancer (NSCLC), outperforming chemotherapy. CAR-T therapies in hematologic malignancies boast complete response rates exceeding 70% in refractory disease settings, although longer-term overall survival (OS) data are still maturing.

Emerging therapies, such as mRNA cancer vaccines and CRISPR-modified T cells, are currently under evaluation. While preliminary results are promising, robust survival data are still pending. Overall, immunological and targeted therapies show superior efficacy in defined subpopulations, often with greater durability than conventional treatments.⁵¹

Toxicity Profiles:

Toxicity remains a pivotal factor in therapy selection. Chemotherapy and radiotherapy are associated with well-documented adverse events, including myelosuppression, mucositis, organ toxicity, and risk of secondary malignancies. Targeted therapies typically reduce systemic toxicity but introduce class-specific adverse effects such as hepatotoxicity (e.g., tyrosine kinase inhibitors), hypertension (e.g., VEGF inhibitors), and dermatologic issues.⁵²

Immunological therapies have distinct toxicity patterns. Immune checkpoint inhibitors can induce immune-related adverse events (irAEs), which can affect various organs, including the skin, lungs, endocrine organs, and gastrointestinal tract. Although manageable in most cases, they can be fatal if not addressed promptly. CAR-T therapies are notable for acute toxicities like cytokine release syndrome (CRS) and neurotoxicity, necessitating intensive monitoring and specialised centres.

Emerging therapies vary widely in safety profiles. Oncolytic viruses and mRNA vaccines are generally well-tolerated, but their long-term effects are under investigation. CRISPR therapies raise concerns about off-target gene edits and immunogenicity. The complexity of toxicity management underscores the importance of comprehensive risk assessment in clinical decision-making.⁵³

Combination Regimens: Synergy and Strategy:

Combination therapies have emerged as a strategy to enhance efficacy and circumvent resistance. Chemo-immunotherapy, exemplified by the KEYNOTE-189 trial (pembrolizumab plus platinum-pemetrexed), has significantly improved overall survival (OS) in advanced non-small cell lung cancer (NSCLC) compared to chemotherapy alone. Similarly, radiation-immunotherapy combinations aim to exploit immunogenic cell death and enhance systemic antitumour immunity.⁵⁴

Targeted-immunotherapy combinations are also under active investigation. For instance, combining BRAF inhibitors with PD-1 blockade in melanoma has shown synergistic effects. These regimens seek to leverage complementary mechanisms, but toxicity and sequencing remain critical considerations.⁵⁵

Rational design based on tumour biology, immune profiling, and pharmacodynamics is essential to maximise benefit and minimise harm. Ongoing trials and real-world data are expected to refine optimal combination strategies.

Limitations: Financial Toxicity and Heterogeneity in Response:

The high cost of novel therapies imposes a substantial financial burden on patients and healthcare systems, a phenomenon known as financial toxicity. This issue is particularly acute for therapies requiring long-term administration or complex manufacturing (e.g., CAR-T cells, personalised mRNA vaccines). Insurance coverage variability and high out-of-pocket costs can limit adherence and exacerbate health disparities. Additionally, heterogeneity in therapeutic response poses a fundamental limitation. Factors such as tumour mutational burden, immune infiltration, genetic variants, and the microbiome influence treatment outcomes. While precision medicine strives to address this variability, predictive biomarkers are not universally available or validated.⁵⁶

Table 3. Major Adverse Events Across Cancer Therapies

Therapy Type	Common Adverse Events	Severe Adverse Events (>Grade 3)	Management Strategies
Chemotherapy	Nausea, fatigue, alopecia, cytopenias	Febrile neutropenia, sepsis, anaemia	Antiemetics, G-CSF, transfusions
Radiotherapy	Skin irritation, fatigue, localised pain	Radiation pneumonitis, fibrosis, tissue necrosis	Steroids, supportive care
Targeted Therapy	Diarrhoea, rash, hypertension	QT prolongation, liver toxicity, bleeding risk	Dose adjustments, antihypertensives
Checkpoint Inhibitors	Rash, fatigue, diarrhoea	Immune-mediated colitis, pneumonitis, hepatitis	Corticosteroids, immunosuppressants
CAR-T Therapy	Fever, cytopenias	Cytokine Release Syndrome (CRS), neurotoxicity	Tocilizumab, ICU care, corticosteroids
Oncolytic Viruses	Flu-like symptoms, injection site pain	Systemic inflammation, rare anaphylaxis	Antipyretics, hospitalisation if needed
mRNA/CRISPR-Based	Injection site pain, fever	Off-target effects (experimental)	Preclinical monitoring; ongoing trials

Comparative evaluation reveals that while newer therapies offer improved efficacy and tolerability in select populations, challenges such as toxicity management, access inequities, and financial burden persist. The future of oncology lies in integrative, personalised approaches supported by global health equity and biomarker-driven innovation.

6. Future Directions & Innovations:

As the cancer treatment landscape continues to evolve, the convergence of advanced technologies, systems biology, and real-world clinical insights is setting the stage for a new era in oncology. Future therapeutic progress will be defined not only by novel drug development but also by the intelligent integration of multi-dimensional data to personalise and optimise care. This section outlines several pivotal frontiers shaping the future of cancer therapy, including precision oncology, artificial intelligence (AI), modulation of the tumour microenvironment, microbiome-based strategies, and the integration of real-world evidence (RWE).⁵⁷

Precision Oncology and Multi-Omics Integration:

Precision oncology aims to tailor treatment strategies to the molecular characteristics of individual tumours. Traditionally focused on single-gene alterations (e.g., EGFR, BRAF), the field is expanding to include comprehensive multi-omics profiling, which integrates genomics, transcriptomics, proteomics, epigenomics, and metabolomics. This systems-level understanding enables the identification of complex oncogenic networks, resistance mechanisms, and actionable vulnerabilities.⁵⁸

Advanced platforms such as whole-exome sequencing (WES) and single-cell RNA sequencing (scRNA-seq) are providing unprecedented resolution into tumour heterogeneity and clonal evolution. Integrative analysis tools are being used to design personalised therapeutic regimens, predict treatment responses, and guide clinical trial enrolment. Multi-omics integration is also catalysing the development of novel biomarkers for early detection, prognosis, and therapeutic monitoring, moving the field closer to real-time, adaptive oncology.⁵⁹

AI-Driven Clinical Decision Support:

Artificial intelligence is revolutionising clinical decision-making by enabling high-throughput data analysis and predictive modelling. Machine learning algorithms can identify patterns in imaging, pathology, genomics, and electronic health records to stratify risk, recommend therapies, and monitor disease progression.

Clinical decision support systems (CDSS) powered by AI are being integrated into oncology workflows to enhance diagnostic accuracy, reduce care variability, and support evidence-based treatment choices. For example, IBM Watson for Oncology has been tested in multiple healthcare settings to provide treatment recommendations based on NCCN guidelines and peer-reviewed literature.⁶⁰

Future applications include real-time analytics during tumour board discussions, AI-guided adaptive trial designs, and digital twins that simulate disease and treatment responses for individual patients.⁶¹

Tumour Microenvironment Reprogramming:

The tumour microenvironment (TME) plays a critical role in cancer progression, immune evasion, and therapeutic resistance. Comprising stromal cells, immune infiltrates, vasculature, and extracellular matrix, the tumour microenvironment (TME) offers multiple targets for therapeutic intervention. Strategies to reprogram the TME include inhibiting immunosuppressive cells (e.g., regulatory T cells, myeloid-derived suppressor cells), normalising abnormal vasculature, and modifying extracellular matrix components to enhance drug penetration. Agents targeting TGF-β, IDO, and CSF-1R are currently under investigation.⁶²

Innovative approaches also include the use of oncolytic viruses and nanotechnology to deliver immune modulators directly into the tumour microenvironment (TME). These efforts aim to convert immunologically “cold” tumours into “hot” ones, enhancing response to immunotherapies.⁶³

Microbiome-Based Therapeutics:

The human microbiome is emerging as a modulator of cancer development, treatment response, and toxicity. Gut microbiota can influence immune function, metabolism, and drug bioavailability, with growing evidence linking microbiome composition to immunotherapy outcomes. Faecal microbiota transplantation (FMT), probiotics, and prebiotics are being explored to manipulate the microbiome in favour of therapeutic benefit. For example, studies have shown that patients with diverse gut microbiota have improved responses to PD-1 inhibitors.⁶⁴

Personalised microbiome modulation, including the use of engineered bacterial strains and microbiome-derived metabolites, represents a novel avenue for enhancing therapeutic efficacy and reducing adverse effects.

Real-World Data Integration into Oncology Trials:

The incorporation of real-world data (RWD) and real-world evidence (RWE) into oncology research is reshaping clinical trial design and post-marketing surveillance. RWD sourced from electronic health records, registries, and wearable devices captures diverse patient experiences outside the constraints of randomised controlled trials (RCTs).⁶⁵

Regulatory bodies, such as the FDA and EMA, are increasingly incorporating real-world evidence (RWE) into drug approval and label expansion decisions. Hybrid trial models, pragmatic trials, and synthetic control arms are being used to accelerate evidence generation and improve trial inclusivity. RWE integration also enhances pharmacovigilance, health economics assessments, and quality-of-care evaluations, promoting a more patient-centred approach to oncology.

Future innovations in cancer therapy will depend on the successful fusion of biological insight, computational power, and real-world context. Precision oncology, AI, microenvironment modulation, and microbiome-based approaches offer promising avenues for transforming treatment paradigms. Real-world data (RWD) ensures that these advances are grounded in practical, inclusive care. Collaborative, interdisciplinary efforts will be essential to fully realise these innovations and improve outcomes for all cancer patients.⁶⁶

CONCLUSION:

Cancer therapy is evolving towards precision, integration, and personalisation. While conventional treatments such as surgery, chemotherapy, and radiotherapy remain foundational, their combination with targeted and immune-based approaches enhances efficacy and reduces toxicity. Emerging innovations, including gene editing, oncolytic virotherapy, mRNA platforms, and nanomedicine, offer the potential to overcome current therapeutic limitations. Progress will depend on biomarker-guided selection, adaptive trial designs, and multidisciplinary collaboration. Ensuring affordability and equitable global access is crucial for translating scientific advances into widespread clinical benefit. The ultimate goal remains durable cancer control and improved quality of life for patients worldwide.

CONFLICT OF INTEREST:

The authors declare that they have no conflict of interest.

REFERENCES:

1. Cao W, Chen H-D, Yu Y-W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal. 2021;134(7):783–791; doi: 10.1097/CM9.0000000000001474.

2. Vitale I, Shema E, Loi S, et al. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021; 27(2): 212–224; doi: 10.1038/s41591-021-01233-9.

3. Liu B, Zhou H, Tan L, et al. Exploring treatment options in cancer: tumor treatment strategies. Sig Transduct Target Ther 2024;9(1):175; doi: 10.1038/s41392-024-01856-7.

4. Debela DT, Muzazu SG, Heraro KD, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Medicine. 2021; 9:20503121211034366; doi: 10.1177/20503121211034366.

5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clinicians. 2021; 71(3): 209–249; doi: 10.3322/caac.21660.

6. Urla C, Fuchs J, Grimm A, et al. Interdisciplinary surgical approach enables complete tumor resection with preservation of neurological function in specific conditions of pediatric solid malignancies. J Cancer Res Clin Oncol. 2023; 149(8): 4497–4507; doi: 10.1007/s00432-022-04273-x.

7. Sorensen L, Lam AB, Moore VA, et al. Investigating perioperative interventions to enhance surgical outcomes for older adults with cancer: A systematic review. JCO. 2024; 42(16_suppl): e13765–e13765; doi: 10.1200/JCO.2024.42.16_suppl.e13765.

8. Burotto M, Wilkerson J, Stein WD, et al. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Seminars in Oncology. 2019; 46(1): 83–99; doi: 10.1053/j.seminoncol.2019.01.002.

9. Ashley S, Choudhury A, Hoskin P, et al. Radiotherapy in metastatic bladder cancer. World J Urol. 2024; 42(1): 47; doi: 10.1007/s00345-023-04744-x.

10. Verginadis II, Citrin DE, Ky B, et al. Radiotherapy toxicities: mechanisms, management, and future directions. The Lancet. 2025; 405(10475): 338–352; doi: 10.1016/S0140-6736(24)02319-5.

11. Behranvand N, Nasri F, Zolfaghari Emameh R, et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother. 2022; 71(3): 507–526; doi: 10.1007/s00262-021-03013-3.

12. Pache MM, Thorat AS, Mule RR, et al. Recent advances in the use of alkaloids as therapeutic agents: A pharmacognostic perspective. World Journal of Pharmaceutical Research. 2025; 14(2): 538–552.

13. López ÁG, Iarosz KC, Batista AM, et al. The role of dose density in combination cancer chemotherapy. Communications in Nonlinear Science and Numerical Simulation. 2019; 79: 104918; doi: 10.1016/j.cnsns.2019.104918.

14. Pache M, Nikam S. Antibiotic Resistance: Current Challenges and Future Directions. Int J of Pharm Sci. 2025; 3(1): 1600–1622; doi: 10.5281/ZENODO.14690670.

15. Qu Z. Investigating Conventional and Novel Methods for Treatment of Cancer. In: Proceedings of the 12th International Conference on Bioscience, Biochemistry and Bioinformatics ACM: Tokyo Japan; 2023; pp. 103–111; doi: 10.1145/3586139.3586154.

16. Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Sig Transduct Target Ther. 2020; 5(1): 22; doi: 10.1038/s41392-020-0116-z.

17. Huang XL, Khan MI, Wang J, et al. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision. International Journal of Biological Macromolecules. 2021; 180: 739–752; doi: 10.1016/j.ijbiomac.2021.03.075.

18. Pottier C, Fresnais M, Gilon M, et al. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers. 2020; 12(3): 731; doi: 10.3390/cancers12030731.

19. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews. 2020; 86: 102017; doi: 10.1016/j.ctrv.2020.102017.

20. Gupta T, Vinayak S, Telli M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat. 2023; 197(1): 51–56; doi: 10.1007/s10549-022-06780-4.

21. Peterson C, Denlinger N, Yang Y. Recent Advances and Challenges in Cancer Immunotherapy. Cancers. 2022; 14(16): 3972; doi: 10.3390/cancers14163972.

22. Pache MM, Pangavhane RR. Immunotherapy in Autoimmune Diseases: Current Advances and Future Directions. Asian Journal of Pharmaceutical Research. 2025; 15(2): 183–191; doi: 10.52711/2231-5691.2025.00030.

23. Bod L, Kye Y-C, Shi J, et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature. 2023; 619(7969): 348–356; doi: 10.1038/s41586-023-06231-0.

24. Zhou Y, Zhang Y, Guo G, et al. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer. Clinical and Translational Med. 2020; 10(1): 107–115; doi: 10.1002/ctm2.14.

25. Chakrabarti R, Siegel D, Biran N. The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2025; 25(2): 96–108; doi: 10.1016/j.clml.2024.08.004.

26. Chohan KL, Siegler EL, Kenderian SS. CAR-T Cell Therapy: the Efficacy and Toxicity Balance. Curr Hematol Malig Rep 2023;18(2):9–18; doi: 10.1007/s11899-023-00687-7.

27. Fan T, Zhang M, Yang J, et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Sig Transduct Target Ther. 2023; 8(1): 450; doi: 10.1038/s41392-023-01674-3.

28. Saxena M, Van Der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6): 360–378; doi: 10.1038/s41568-021-00346-0.

29. Zhang S, Zhao L, Guo M, et al. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses. J Immunother Cancer. 2023; 11(7): e006785; doi: 10.1136/jitc-2023-006785.

30. Xue D, Hsu E, Fu Y-X, et al. Next-generation cytokines for cancer immunotherapy. Antibody Therapeutics 2021;4(2):123–133; doi: 10.1093/abt/tbab014.

31. Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023; 14: 1167975; doi: 10.3389/fimmu.2023.1167975.

32. Kewan T, Mirza S, Pine AB, et al. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood. 2023; 142(Supplement 1):2132–2132; doi: 10.1182/blood-2023-187295.

33. Pache M, Kedar H, Kond S, et al. Pharmacological Management of Neurodegenerative Disorders: Current and Future Approaches. Int J Sci R Tech. 2025; 2(3): 405–520; doi: 10.5281/ZENODO.15074000.

34. Li S, De Camargo Correia GS, Wang J, et al. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers. 2023; 15(11): 2899; doi: 10.3390/cancers15112899.

35. Ghule RJ, Jadhav PN, Sanap YN, Pache MM, Darekar AB. Tumour-derived extracellular vesicles in chemotherapy resistance: Molecular pathways, clinical implications and therapeutic opportunities. Asian J Res Pharm Sci. 2025; 15(4): 371–380. doi:10.52711/2231-5659.2025.00055

36. Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021; 374(6573): 1325–1326; doi: 10.1126/science.abk3436.

37. Shalhout SZ, Miller DM, Emerick KS, et al. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023; 20(3): 160–177; doi: 10.1038/s41571-022-00719-w.

38. Chen X-Z, Guo R, Zhao C, et al. A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. Front Pharmacol. 2022; 13: 939090; doi: 10.3389/fphar.2022.939090.

39. Pache MM, Pangavhane RR, Nikam SV, et al. CRISPR-Cas9 in Pharmaceutical Research: Applications, Challenges, Ethical Considerations and Future Directions. Asian Journal of Pharmacy and Technology. 2025.

40. Mueller KP, Piscopo NJ, Forsberg MH, et al. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression. J Immunother Cancer 2022;10(9):e004446; doi: 10.1136/jitc-2021-004446.

41. Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol. 2022; 13: 1029069; doi: 10.3389/fimmu.2022.1029069.

42. Rappaport AR, Kyi C, Lane M, et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024; 30(4): 1013–1022; doi: 10.1038/s41591-024-02851-9.

43. Sun J, Yang Z, Teng L. Nanotechnology and Microtechnology in Drug Delivery Systems. Dose-Response 2020;18(2):155932582090781; doi: 10.1177/1559325820907810.

44. Hristova-Panusheva K, Xenodochidis C, Georgieva M, et al. Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology. Pharmaceuticals. 2024; 17(6): 677; doi: 10.3390/ph17060677.

45. Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Annals of Oncology. 2024; 35(1): 29–65; doi: 10.1016/j.annonc.2023.10.125.

46. Pache MM, Pangavhane RR, Jagtap MN, et al. The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges. Asian J Res Pharm Sci. 2025; 15(1): 61–67; doi: 10.52711/2231-5659.2025.00009.

47. Bhinder B, Gilvary C, Madhukar NS, et al. Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discovery. 2021; 11(4): 900–915; doi: 10.1158/2159-8290.CD-21-0090.

48. Anand U, Dey A, Chandel AKS, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2023; 10(4): 1367–1401; doi: 10.1016/j.gendis.2022.02.007.

49. Abraham I, Obeng-Kusi M, Roe D, et al. Comparative efficacy of later-line therapies for metastatic colorectal cancer (mCRC) using novel methods for patient survival data reconstruction and network meta-analysis (NMA) of survival curves. JCO. 2023; 41(16_suppl):e15611–e15611; doi: 10.1200/JCO.2023.41.16_suppl.e15611.

50. Min H-Y, Lee H-Y. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022; 54(10): 1670–1694; doi: 10.1038/s12276-022-00864-3.

51. Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations. The Lancet. 2021; 397(10278): 1010–1022; doi: 10.1016/S0140-6736(20)32598-8.

52. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA A Cancer J Clinicians. 2020; 70(2): 86–104; doi: 10.3322/caac.21596.

53. Shah RR, Curigliano G. Safety of Novel Targeted Therapies in Oncology. Drug Saf. 2019; 42(2): 157–158; doi: 10.1007/s40264-018-0770-z.

54. Nair NU, Greninger P, Zhang X, et al. A landscape of response to drug combinations in non-small cell lung cancer. Nat Commun. 2023; 14(1): 3830; doi: 10.1038/s41467-023-39528-9.

55. Tan AC, Bagley SJ, Wen PY, et al. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021; 9(7): e002459; doi: 10.1136/jitc-2021-002459.

56. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment. CA A Cancer J Clinicians. 2018; 68(2): 153–165; doi: 10.3322/caac.21443.

57. Masina R, Caldas C. Precision Cancer Medicine 2.0—Oncology in the postgenomic era. Molecular Oncology. 2024; 1878–0261.13707; doi: 10.1002/1878-0261.13707.

58. Akhoundova D, Rubin MA. Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future. Cancer Cell. 2022; 40(9): 920–938; doi: 10.1016/j.ccell.2022.08.011.

59. Zheng J, Lu W, Wang C, et al. Unfolding the mysteries of heterogeneity from a high-resolution perspective: integration analysis of single-cell multi-omics and spatial omics revealed functionally heterogeneous cancer cells in ccRCC. Aging. 2024; 16(13): 10943–10971; doi: 10.18632/aging.205974.

60. Giordano C, Brennan M, Mohamed B, et al. Accessing Artificial Intelligence for Clinical Decision-Making. Front Digit Health. 2021; 3: 645232; doi: 10.3389/fdgth.2021.645232.

61. Madhavan S, Beckman RA, McCoy MD, et al. Envisioning the future of precision oncology trials. Nat Cancer. 2021; 2(1): 9–11; doi: 10.1038/s43018-020-00163-8.

62. El-Tanani M, Rabbani SA, Babiker R, et al. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Letters. 2024; 591: 216894; doi: 10.1016/j.canlet.2024.216894.

63. Su W, Qiu W, Li S, et al. A Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis. Advanced Materials. 2023; 35(11): 2209379; doi: 10.1002/adma.202209379.

64. Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer. Science. 2021; 371(6536): eabc4552; doi: 10.1126/science.abc4552.

65. Berger ML, Ganz PA, Zou KH, et al. When Will Real-World Data Fulfill Its Promise to Provide Timely Insights in Oncology? JCO Clin Cancer Inform. 2024; 8: e2400039; doi: 10.1200/CCI.24.00039.

66. Anonymous. Innovations in Cancer Research and Treatment. Au Herb Insight. 2024; 7(1): 1–12; doi: 10.25163/ahi.7120050.

Received on 25.08.2025      Revised on 07.11.2025

Accepted on 12.01.2026 Published on 06.07.2026

Available online from July 20, 2026

Asian J. Pharm. Res. 2026; 16(3):295-305.

DOI: 10.52711/2231-5691.2026.00044

©Asian Pharma Press All Right Reserved

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.